Median Technologies and PASREL-Imagerie, announced the signing of an agreement to deliver cutting-edge imaging biomarkers for the development of new oncology drugs in the era of precision medicine. By leveraging its expertise in medical imaging, PASREL-ImagerIE will bring its know-how and support to Median in the implementation of advanced imaging biomarkers for early phase oncology trials. New capabilities resulting from this agreement create a strong and unique differentiator for Median's iCRO offering, compared to the offerings of other imaging vendors targeting the biopharmaceutical industry.

Whereas oncology clinical trials rely primarily on relatively standard imaging assessments, the ability to implement advanced imaging biomarkers - including molecular imaging - specifically linked to the drug's mechanism of action would help better understand the biological effect of each drug and collect additional evidence of efficiency during the early phases of clinical trials. The resulting knowledge would enable the biopharmaceutical industry to develop new drugs more effectively, while making the drug development cycle safer and shorter. PASREL-Imagersie brings together 33 technical platforms and has a long-lasting experience of industry partnerships to support innovative drug developments.

PASREL-Imageie has unique scientific and medical expertise in the entire imaging value chain, from radiotracer production to image acquisition and processing for statistical and quantitative analysis.